

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC. AND APOTEX CORP.,
Petitioners

v.

AUSPEX PHARMACEUTICALS, INC.,
Patent Owner

Case IPR2021-01507
U.S. Patent No. 8,524,733
Issued: September 3, 2013

Title:
BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2

DECLARATION OF JEFFREY P. JONES, PH.D.

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	1
II. EXPERIENCE AND QUALIFICATIONS.....	1
III. LEGAL STANDARDS USED IN MY ANALYSIS.....	4
A. Prior Art.....	4
B. Person of Ordinary Skill in the Art	4
C. Obviousness.....	5
IV. THE '733 PATENT	8
A. The Alleged Invention.....	8
B. The Challenged Claims	8
C. Claim Construction.....	9
V. BACKGROUND.....	10
A. Tetrabenazine Was a Well-Known Therapeutic with Known Drawbacks	11
B. The Methoxy Groups of Tetrabenazine Were Known to Be Essential for Its Activity and Were Also Sites of Metabolism	13
C. Strategic Deuteration Was Known to Slow Metabolism in Compounds Like Tetrabenazine.....	17
D. Deuteration Was Known to Impart Other Therapeutic Benefits	23
E. The Patentee's Arguments Made During Prosecution Were Incorrect.....	23
1. The Effects of Deuteration of Tetrabenazine's Methoxy Groups Were Predictable	24
2. The Patentee Did Not Demonstrate Unexpected Results	29
VI. OBVIOUSNESS.....	34

A.	Claims 1-3 of the '733 Patent Would Have Been Obvious Based on Zheng in View of Naicker '921 and Kohl.....	34
1.	A POSITA Would Have Been Motivated to Combine Prior Art Teachings Regarding Tetrabenazine and Deuteration to Arrive at the Claimed Invention	35
a.	Zheng Would Have Motivated a POSITA to Select Tetrabenazine as a Lead Compound and Seek to Improve It	35
b.	Naicker '921 Would Have Motivated a POSITA to Deuterate Tetrabenazine in Order to Improve Its Activity and Highlights Methoxy Groups Specifically as Promising Sites for Deuteration.....	36
c.	Kohl Discloses Benefits from Deuterating Methoxy Groups and Also Teaches the Other Claim Limitations	40
2.	A POSITA Would Have Had a Reasonable Expectation of Arriving at the Claimed Compounds and Compositions	43
3.	The Patentee Failed to Show Unexpected Results Sufficient to Rebut Obviousness.....	44
B.	Claims 1-3 of the '733 Patent Would Have Been Obvious Based on Zheng in View of Foster AB and Kohl	45
1.	A POSITA Would Have Been Motivated to Combine Prior Art Teachings Regarding Tetrabenazine and Deuteration to Arrive at the Claimed Invention	46
a.	Zheng Would Have Motivated a POSITA to Select Tetrabenazine as a Lead Compound and Seek to Improve It	46
b.	Foster AB Would Have Motivated a POSITA to Deuterate Tetrabenazine in Order to Improve Tetrabenazine's Activity and Highlights Methoxy Groups as Promising Sites for Deuteration	47

c.	Kohl Discloses Benefits from Deuterating Methoxy Groups and Also Teaches Other Dependent Claim Limitations.....	48
2.	A POSITA Would Have Had a Reasonable Expectation of Arriving at the Claimed Compounds and Compositions	49
3.	The Patentee Failed to Show Unexpected Results Sufficient to Rebut Obviousness.....	50
C.	Claims 1-3 of the '733 Patent Would Have Been Obvious Based on Gano in View of Schwartz and Gant '991	50
1.	A POSITA Would Have Been Motivated to Combine Prior Art Teachings Regarding Tetrabenazine and Deuteration to Arrive at the Claimed Invention	51
a.	Gano Would Have Motivated a POSITA to Select Tetrabenazine as a Lead Compound and Seek to Improve It	51
b.	Schwartz Teaches that the Methoxy Groups of Deutetrabenazine Were Sites of Metabolism	52
c.	Gant '991 Would Have Motivated a POSITA to Deuterate the Methoxy Groups of Tetrabenazine and Discloses the Other Claim Limitations.....	53
2.	A POSITA Would Have Had a Reasonable Expectation of Arriving at the Claimed Compounds and Compositions	57
3.	The Patentee Has Not Shown Unexpected Results Sufficient to Rebut Obviousness.....	58
VII.	CONCLUSIONS.....	59

LIST OF EXHIBITS

Exhibit No.	Description
1001	U.S. Patent No. 8,524,733, “Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2” (the “ <u>733 patent</u> ”)
1002	Declaration of Jeffrey P. Jones, Ph.D. (the “ <u>Jones Decl.</u> ”)
1003	Zheng, G. et al., <i>Vesicular Monoamine Transporter 2: Role as a Novel Target for Drug Development</i> , THE AAPS JOURNAL, 8(4):E682-E692 (2006) (“ <u>Zheng</u> ”)
1004	Naicker, S. et al., U.S. Patent No. 6,503,921, “Deuterated rapamycin compounds, methods and uses thereof” (“ <u>Naicker '921</u> ”)
1005	Kohl, B. et al., WO 2007/012650, “Isotopically Substituted Proton Pump Inhibitors” (2007) (“ <u>Kohl</u> ”)
1006	Foster A.B. et al., <i>Isotope effects in O- and N-demethylations mediated by rat liver microsomes: An application of direct insertion electron impact mass spectrometry</i> , CHEM.-BIOL. INTERACTIONS, 9:327-340 (1974) (“ <u>Foster AB</u> ”)
1007	Gano, K.W., U.S. Patent No. 8,039,627, “Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto” (“ <u>Gano</u> ”)
1008	Schwartz, D.E. et al., <i>Metabolic studies of tetrabenazine, a psychotropic drug in animals and man</i> , BIOCHEMICAL PHARMACOLOGY, 15:645-655 (1966) (“ <u>Schwartz</u> ”)
1009	Gant, T.G. et al., U.S. Pat. Pub. No. 2008/0280991, “Substituted Naphthalenes” (2008) (“ <u>Gant '991</u> ”)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.